Treating lipids in cardiovascular disease: New directions

European Heart Journal, Supplement

Volumn 3, Issue B, 2001, Pages

  Wiklund, O ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Cerivastatin; High density lipoprotein; Low density lipoprotein; Statins

Indexed keywords

ANTILIPEMIC AGENT; CERIVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034946847     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90054-9     Document Type: Conference Paper

References (26)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S)
3. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolemia: The pivotal placebo-controlled trial
4. Low-density lipoprotein-independent effects of statins
5. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes
6. High density lipoprotein cholesterol and mortality. The Framingham Heart Study
7. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study
8. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
9. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
10. Comparative dose efficacy study of atorvastatin versus simvastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
11. Efficacy and safety of cerivastatin, 0.2 and 0.4 mg, in patients with primary hypercholesterolaemia
12. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
13. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
14. Cerivastatin gender effect: Sub-analyses of results from multi-national, randomised, double-blind study
15. Detection and quantification of LDL subfractions
16. The response-to-retention hypothesis to early atherogenesis
17. The response-to-retention hypothesis of atherogenesis reinforced
18. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
19. Differential uptake of proteoglycan selected subfractions of low density lipoprotein by human macrophages
20. Influence of plasma lipid and LDL subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
21. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction
22. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects
23. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production
24. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs
25. Efficacy and safety of cerivastatin/fenofibrate combination therapy for hypercholesterolemia